26 withdrawn. 26 Phase 3, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 26 | Withdrawn 26 |
| Phase 2 | 6 | Withdrawn 6 |
Follow Bronchial Diseases: new trials by email Literature Review of Bronchial Diseases trials Research Report on Bronchial Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Formoterol 6 mcg/Fluticasone 125 mcg by Eurofarma Laboratórios S.A. Versus Alenia® 6 mcg/200 mcg in Patients With Asthma (FORASMA) N0783, Alenia® (Formoterol 6 mcg / Budesonide 200 mcg) - Moderate Asthma | Phase 3 | Withdrawn | Eurofarma Laboratorios S.A. | 2026-10-01 | 2026-10-23 | |
| Study of Dupilumab 300 mg Every Other Week After Endoscopic Sinus Surgery in Patients With Allergic Fungal Rhinosinusitis (AFRS) on a Background Therapy With Intranasal Corticosteroid Spray Dupilumab - Allergic Fungal Rhinosinusitis (AFRS), Chronic Rhinosinusitis (CRS) | Phase 3 | Withdrawn | National Institute on Deafness and Other Communication Disorders (NIDCD) | 2024-07-17 | 2024-07-25 | |
| Terbutaline Sulfate in Adults With Asthma Terbutaline - Asthma | Phase 2 / Phase 3 | Withdrawn | Kanecia Obie Zimmerman | 2023-07-07 | 2026-01-22 | |
| Pharmacodynamic Bioequivalence Study of Albuterol Sulfate Inhalation Aerosol, 0.09 mg Albuterol Base/ Inhalation Methacholine Chloride, Albuterol Sulfate HFA 0.09 mg (Reference), Albuterol Sulfate HFA 0.18 mg (Reference) - Bronchial Asthma | Phase 3 | Withdrawn | Aurobindo Pharma Ltd | 2022-04-01 | 2022-05-20 | |
| Investigating the Effects of QVM149 on MRI Ventilation Defects QVM149, High Dose Dual Therapy (ICS/LABA) - Asthma | Phase 3 | Withdrawn | Dr. Grace Parraga | 2021-12-01 | 2021-12-14 | |
| Efficacy of Magnesium Sulfate Bolus in Pediatric Patients With Bronchiolitis Magnesium Sulfate - Bronchiolitis, Viral | Phase 2 / Phase 3 | Withdrawn | University of Louisville | 2021-07-21 | 2026-05-11 | |
| The Role of Ketamine as an Adjuvant Therapy for Children With Acute Status Asthmaticus Ketamine - Status Asthmaticus | Phase 3 | Withdrawn | Augusta University | 2020-01-01 | 2024-02-06 | |
| Beclomethasone Dipropionate HFA in Adult and Adolescent Subjects With Persistent Asthma Beclomethasone 800 µg per day, Placebo, Beclomethasone 400 µg per day - Asthma | Phase 3 | Withdrawn | Adamis Pharmaceuticals Corporation | 2019-02-01 | 2019-07-17 | |
| Beclomethasone Dipropionate HFA in Adult and Adolescent Subjects With Mild to Moderate Persistent Asthma Placebo, 400 µg per day Beclomethasone, 200 µg per day Beclomethasone - Asthma | Phase 3 | Withdrawn | Adamis Pharmaceuticals Corporation | 2019-02-01 | 2019-07-17 | |
| Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled Asthma FF/UMEC/VI, FP/SAL, Tiotropium - Asthma | Phase 3 | Withdrawn | GlaxoSmithKline | 2019-01-18 | 2019-03-25 | |
| A Single-Arm Study to Evaluate Administration of Lebrikizumab by Participants or Caregivers in the Home Setting Lebrikizumab, Prefilled Syringes - Asthma | Phase 3 | Withdrawn | Hoffmann-La Roche | 2015-09-29 | 2018-04-25 | |
| Randomized, Placebo-controlled Study Comparing Efficacy of Fluticasone/Salmeterol Combination to Advair in Asthmatics Fluticasone propionate 100 mcg / salmeterol 50 mcg, Generic fluticasone propionate 100 mcg / salmeterol 50 mcg, Placebo - Asthma | Phase 3 | Withdrawn | Actavis Inc. | 2015-09-01 | 2019-07-05 | |
| Study of Efficacy and Safety of NVA237 in Patients With Poorly Controlled Asthma NVA237, Placebo to NVA237, salbutamol/ albuterol - Asthma | Phase 3 | Withdrawn | Novartis Pharmaceuticals | 2015-03-01 | 2015-04-13 | |
| A Study of Alegitazar in Patients With Type 2 Diabetes And Chronic Kidney Disease (Alerenal Study) Aleglitazar, Placebo - Diabetes Mellitus Type 2, Kidney Disease, Chronic | Phase 3 | Withdrawn | Hoffmann-La Roche | 2013-12-01 | 2016-11-02 | |
| Efficacy and Safety of Mometasone Furoate for Persistent Asthma Previously Treated With Low-Dose Inhaled Glucocorticosteroids (ICS) (Study P06115) SCH 32088 mometasone furoate (MF) metered-dose inhaler, Placebo metered-dose inhaler BID - Asthma | Phase 3 | Withdrawn | Organon and Co | 2012-06-01 | 2022-02-16 | |
| The Effect of Perioperative Pregabalin on the Incidence of Chronic Post-thoracotomy Pain Syndrome Pregabalin - Chronic Pain | Phase 3 | Withdrawn | Queen's University | 2012-05-01 | 2012-04-11 | |
| Pilot Study of Magnesium Infusions in Pediatric Asthma Magnesium Sulfate, Placebo - Asthma | Phase 2 / Phase 3 | Withdrawn | University of Louisville | 2012-01-01 | 2017-03-30 | |
| A Study of a New Asthma Medicine in Asthmatics Whose Asthma Worsens With Exercise Fluticasone Furoate/Vilanterol Inhalation Powder, Fluticasone Propionate Inhalation Powder - Asthma | Phase 3 | Withdrawn | GlaxoSmithKline | 2012-01-01 | 2014-06-23 | |
| Randomized Controlled Trial of Silymarin in Asthma Oral Silymarin, Oral Silymarin, maintenance dose, Placebo - Atopic Asthma | Phase 2 / Phase 3 | Withdrawn | Vanderbilt University | 2010-09-01 | 2014-02-24 | |
| Bronchoprotective Effect of Arformoterol in Children With Exercise-Induced Bronchospasm (EIB) arformoterol, formoterol, placebo - Exercise-induced Bronchospasm | Phase 3 | Withdrawn | University of New Mexico | 2008-04-01 | 2015-12-11 |
Showing 20 of 26. Sign in to see all of them.
Asthma (21) · Bronchiolitis Obliterans Syndrome (3) · Asthma, Exercise-Induced (2) · Allergic Fungal Sinusitis (1) · Bronchiolitis, Viral (1) · Chronic Pain (1) · Diabetes Mellitus, Type 2 (1) · Emphysema (1) · Heart Failure (1) · Kidney Diseases (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Lung Diseases (1) · Motor Activity (1) · Nasal Polyps (1) · Pain (1)
Respiratory Tract Diseases (26) · Immune System Diseases (25) · Lung Diseases, Obstructive (25) · Lung Diseases (24) · Hypersensitivity (22) · Hypersensitivity, Immediate (22) · Respiratory Hypersensitivity (22) · Bronchiolitis (4) · Bronchitis (4) · Pathological Conditions, Signs and Symptoms (4) · Bronchiolitis Obliterans (3) · Graft vs Host Disease (3) · Organizing Pneumonia (3) · Chronic Disease (2)
Albuterol (3) · Beclomethasone (2) · Fluticasone (2) · Formoterol Fumarate (2) · Magnesium Sulfate (2) · Metered Dose Inhalers (2) · montelukast (2) · Adrenal Cortex Hormones (1) · Adrenergic beta-Agonists (1) · Budesonide (1) · Colchicine (1) · Dasatinib (1) · Fluticasone-Salmeterol Drug Combination (1) · Glycopyrrolate (1) · Ketamine (1)
Adamis Pharmaceuticals Corporation (2) · GlaxoSmithKline (2) · Hoffmann-La Roche (2) · Organon and Co (2) · University of Louisville (2) · Actavis Inc. (1) · Alung Technologies (1) · Augusta University (1) · Aurobindo Pharma Ltd (1) · Bristol-Myers Squibb (1) · Children's Hospital Medical Center, Cincinnati (1) · Dr. Grace Parraga (1) · Eurofarma Laboratorios S.A. (1) · Kanecia Obie Zimmerman (1) · Milton S. Hershey Medical Center (1)
United States (7) · Canada (2) · United Kingdom (2) · Germany (1) · Hungary (1) · Italy (1) · Netherlands (1) · Poland (1) · Russia (1)
Dennis Carlo (2) · Beverley Patterson, PhD (1) · Elliot Israel (1) · Grace E Parraga, PhD (1) · Hengameh Raissy, Pharm.D. (1) · Homer A. Boushey (1) · Jason Lang, MD (1) · John W Berkenbosch, MD (1) · Jorge E Zamora, MD (1) · Joseph Marialouis, MD (1) · Joshua Levy, M.D. (1) · Keith Cross, MD (1)
2017 (1), U10HL051823 (1), U10HL051831 (1), U10HL051834 (1), U10HL051843 (1), U10HL051845 (1), U10HL056443 (1), U10HL074073 (1), U10HL074204 (1), U10HL074206 (1), U10HL074208 (1), U10HL074212 (1), U10HL074218 (1), U10HL074225 (1), U10HL074227 (1)